GRI Bio Inc (GRI): Fair Value Consensus
GRI Bio, Inc. (GRI) is a reputable biotech brand specializing in the suppression of tissue fibrosis through T-cell management. The linear price action on the chart, where the indicator stands at 18.49, accompanies the development of immune modulation therapy using NKT cells, which will ensure exclusive pricing power upon commercialization. The company is currently focusing on primary safety trials of its innovative programs for treating internal organ lesions.
Analytical breakdowns for GRI Bio Corp (GRI)
- market value and analyst target forecast:
- stock exchange capitalization data:
- book capitalization indicators:
- debt obligations and liquidity statistics:
- net income and valuation ratios data:
GRI - Net Income|Expected Net Income GRI Bio, Inc.|GRI - P/E Multiple|Market Cap to Projected Earnings GRI Bio Inc|GRI - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio GRI Bio Corp|GRI - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months GRI Bio|GRI - Net earnings per share for the last 12 months|Quarterly EPS earnings growth gribio.com|GRI - Earnings per share growth in current year|Projected earnings per share growth rate for next year GRI Bio, Inc.
Fundamental company analysis:gribio.com, GRI
This indicator aggregates target prices from leading investment houses, measuring average market expectations for the asset's fair value based on fundamental valuations. The trend of the averaged expert benchmark for GRI Bio, Inc. (GRI) reflects market confidence in the success of the company's NKT-therapy clinical trials, where rising targets confirm the resilience of the company's patent moat in the face of stringent FDA regulatory filters.
Competitors of GRI Bio, Inc.
argenx.com (ARGX) - Analyst Target Range|Price Target Chart BioNTech BNTX|Fair Value Consensus ABVX|ADMA Bio - Analyst Consensus Forecast|Analyst Median Target Protagonist Corp PTGX|Immunovant, Inc. (IMVT) - Price Target Chart|Forecast Levels Chart KNSA (kiniksa.com)|GRFS (Grifols) - Analyst Consensus Forecast|ADPT: Fair Value Consensus|Analyst Consensus Forecast CLDX|Analyst Consensus Forecast Aurinia Corp (AUPH)|Price Target Chart BioCryst BCRX|Fair Value Consensus VERA|DNTH - Price Target Chart|Pharvaris NV (PHVS) - Consensus Target|ABCL: Analyst Consensus Forecast|Tourmaline (TRML) - Analyst Consensus Forecast|Consensus Target PGEN|PHAR: Fair Value Consensus|Analyst Consensus Forecast NKTR|Analyst Median Target Upstream Bio, Inc.|Price Target Chart Zenas Biopharma, Inc. ZBIO|IMNM - Consensus Target|GOSS - Price Target Chart|kalvista.com (KALV) - Consensus Target|SEPN (Septerna) - Consensus Target|Pieris Pharma (PVLA) - Analyst Consensus Forecast|Price Target Chart Savara Corp|Broker Consensus Forecast RIGL (Rigel Corp)|Analyst Consensus Forecast ANAB|ATXS - Average Forecast Price|Analyst Consensus Forecast ENGN (enGene)|Analyst Target Range rapt.com|JBIO - Price Target Chart|Fair Value Consensus ACRS (Aclaris Therapeutics, Inc)|KYTX: Analyst Consensus Forecast|TLSA - Analyst Median Target|Consensus Target CABA|VTYX: Fair Value Consensus|Analyst Consensus Forecast THTX|Price Target Chart AVTX (Avalo Therapeutics Inc)|Analyst Consensus Forecast ELDN (Eledon Pharmaceuticals)|Analyst Median Target agenusbio.com (AGEN)|CLYM - Price Target Chart|Average Forecast Price zurabio.com|ATYR (aTyr) - Consensus Target|Adagene Inc. - Fair Value Consensus|IMA (ImageneBio) - Analyst Consensus Forecast|Shattuck Therapeutics (STTK) - Analyst Median Target|Price Target Chart Equillium, Inc. (EQ)|connectbiopharm.com - Broker Consensus Forecast|Analyst Consensus Forecast IMUX (Immunic)|ATRA - Consensus Target|IFRX: Consensus Target|Analyst Median Target x4pharma.com XFOR|ACET: Analyst Consensus Forecast|Analyst Target Range Celularity CELU|Price Target Chart INmune Bio Corp|BRNS: Fair Value Consensus|Analyst Consensus Forecast KZR|Analyst Median Target sabbiotherapeutics.com|Price Target Chart Akari Therapeutics Plc AKTX|ENLV (Enlivex Therapeutics Ltd) - Forecast Levels Chart|Q32 Bio Corp - Analyst Consensus Forecast|Fair Value Consensus GOVX (GeoVax Corp)|EDSA: Analyst Consensus Forecast|ibioinc.com (IBIO) - Analyst Consensus Forecast|Price Target Chart Carisma Therapeutics Inc|XTLB: Fair Value Consensus|Price Target Chart Bolt Biotherapeutics (BOLT)|Consensus Target hcwbiologics.com HCWB|Analyst Consensus Forecast APVO (Aptevo Therapeutics Inc.)|Analyst Consensus Forecast aimimmuno.com AIM|ADTX: Consensus Target|Fair Value Consensus XRTX (XORTX Therapeutics Inc)|HIND: Analyst Consensus Forecast|REVB - Analyst Median Target|Price Target Chart Indaptus Therapeutics|Consensus Target scinai.com (SCNI)|Price Target Chart CalciMedica, Inc. (CALI)|Consensus Target affimed.com AFMD|Allakos - Consensus Target|Analyst Consensus Forecast HOOKIPA Pharma, Inc. HOOK|IGMS - Price Target Chart|ITOS (iteostherapeutics.com) - Broker Consensus Forecast|OCEA: Analyst Consensus Forecast|Average Forecast Price TC BioPharm (Holdings) Plc (TCBP)|THRD (Third Harmonic Bio, Inc) - Analyst Consensus Forecast
